(https://www.marketwatch.com/story/a-new-blood-test-can-help-detect-colon-cancer-but-its-not-as-good-as-the-test-you-hate-to-take-1c5716d0?mod=mw_rss_topstories) is being framed as inferior because 50 million Americans still won't get screened. That's backwards. A test that's 80% as sensitive but 10x easier to administer doesn't fail — it captures demand that didn't exist.

Research these companies